Opis projektu
Określenie stężenia cynku w trakcie choroby nowotworowej dzięki MRI
Szybka diagnoza i terapia raka trzustki jest szczególnie trudna, co prowadzi do niekorzystnych rokowań i niskiego poziomu przeżywalności. Coraz więcej dowodów wskazuje na to, że komórki raka trzustki prezentują niskie poziomy importerów i zawartości cynku, natomiast leczenie jonoforem cynku hamuje rozwój guza. Aby określić stężenie cynku w tkankach, naukowcy w ramach finansowanego przez UE projektu tZR-CA-InVivo chcą opracować narzędzie do diagnostyki obrazowej z zastosowaniem rezonansu magnetycznego, tzn. środek kontrastowy reagujący na cynk. Środek kontrastowy będzie zaprojektowany w taki sposób, aby znaleźć przede wszystkim guza i zapewnić możliwość monitorowania, oraz w razie potrzeby podniesienia, stężenia cynku u pacjentów chorych na raka.
Cel
Pancreatic cancer has the lowest survival rate Pancreatic cancer has the lowest survival rate of all cancers in Europe, the median survival time is only a few months due to the lack of test for early diagnosis, and no effective therapies for metastatic forms. Pancreatic Ductal Adenocarcinoma (PDAC), like prostate and hepatocellular cancers present a down regulation of zinc importers and low zinc content. Treatment with clioquinol, a zinc ionophore, to increase the amount of zinc in the tumor has shown to inhibit tumor growth.
This project aims at creating new tool to better detect PDAC by Magnetic Resonance Imaging, and the evaluation of di zinc ionophore to elevate the content in zinc in the tumor environment.
Using the same modular approach, a normal and a zinc responsive contrast agent targeted to the PDAC will be synthesized by conjugation of a peptidic sequence known to target the tumor bearing a Single Core Multimodal Imaging Platform for quantification, with a peptide functionalized with a normal or zinc responsive contrast agent. After careful characterizations in vitro and ex vivo, they will be used in mice implanted with orthoptic pancreatic tumors.
One of the projects developed by the “Metallic complexes for MRI” group, consist designing and using MRI probe for various substrates, including zinc. The group masters all the techniques to characterize the contrast agents, and the experience researcher (ER) will bring the knowledge about zinc biology, and infrared microscopy to quantify the contrast agent in tissues.
Benefiting from the competitive interdisciplinary environment of CBM, and within the group, the ER will acquire new technical skills, knowledge and network the frontier between chemistry, biology and MRI imaging, in particular working with animal model (mice), to adequately implement the project and complete her skill set to become an independent researcher interested in developing tools to study the role of metals in biological context.
Dziedzina nauki
- medical and health sciencesclinical medicineoncologyprostate cancer
- natural scienceschemical sciencesinorganic chemistrytransition metals
- natural sciencesbiological sciencesbiochemistrybiomolecules
- engineering and technologymedical engineeringdiagnostic imagingmagnetic resonance imaging
- medical and health sciencesclinical medicineoncologypancreatic cancer
Słowa kluczowe
Program(-y)
Temat(-y)
System finansowania
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Koordynator
75794 Paris
Francja